1 elets, even after prolonged stimulation with c-Mpl ligand.

2   The cloning of the gene for the endogenous c-mpl ligand, also known as thrombopoietin, was first re

3 ntrol levels in both models, suggesting that c-mpl ligand can directly or indirectly support the main

4 liferation- and ploidy-promoting factor, the c-Mpl ligand, display increased activities of the ubiqui

5 d with kit ligand, flk2/flt3 ligand, GM-CSF, c-mpl ligand, erythropoietin, and IL-15.

6          The effects of thrombopoietin (TPO; c-mpl ligand), FLT3/FLK-2 ligand (FL), and interleukin-6

7 esponse to a single injection of recombinant c-mpl ligand has not been performed.

8                         Thrombopoietin (TPO, c-mpl ligand) has emerged as a major hematopoietic cytok

9 ces of long-term in vivo expression of human c-mpl ligand in a mouse model were examined.

10          In vivo studies have confirmed that c-mpl ligand is a lineage-dominant cytokine and is the p

11 ombopoietic efficacy of recombinant forms of c-mpl ligand is being actively investigated in preclinic

12                    Thrombopoietin (TPO), the c-Mpl ligand, is the primary physiologic regulator of me

13 numerous studies investigating the action of c-mpl ligand, no reports have defined the in vivo change

14 lls, we cultured mouse fetal livers with the c-Mpl ligand, obtained highly enriched megakaryocyte pop

15  a complementary and synergistic effect with c-Mpl ligands on thrombopoiesis.

16 n of TPO in 1994, 2 recombinant forms of the c-Mpl ligand--recombinant human thrombopoietin (rhTPO) a

17 -expressing transgenic line maintained human c-mpl ligand serum levels of 3 ng/mL.

18                          The recently cloned c-mpl ligand, thrombopoietin (Tpo), has been extensively